Objective To explore the feasibility of laparoscopic operations in the treatment of ovarian benign tumors. Methods A retrospective analysis of 150 cases of ovarian benign tumors treated by laparoscopic surgery (146 cases of oophorocystectomy and 4 cases of adnexectomy) from January 1997 to October 2003 was made. Results Surgery was completed successfully in all the 150 cases and no conversions to open surgery were required. Mild extraperitoneal emphysema was observed in 2 cases and no other complications occurred. The mean blood loss was 100 ml, the mean operation time was 80 min, and the mean length of hospitalization was 4 3 days. A total of 128 cases were followed up for a mean of 3 8 years. Recurrence was found in 4 cases in 38 cases of endometriosis cysts. Among 15 patients complicated with infertility, conception occurred in 6 patients after surgery, with a pregnancy rate of 40%. Conclusions Laparoscopic surgery is safe and effective for ovarian benign tumors provided patients are properly selected.

AIM: To study the role of protein kinase B (PKB) in tryptase-induced gene expression on ECV304 cells. METHODS: The expression of PKB, transcript factor AP-1 and NF-?B P65, IL-8, JNK, p38MAPK, and the activity of PKB were measured using RT-PCR and Western blotting. RESULTS: Tryptase at concentration of 1 ?g/L increased the activity of PKB by promoting PKB phosphorylation, promoted the expression of PKB, chemokine IL-8, transcription factor AP-1 and NF-?B P65, however, no changes of JNK and p38MAPK was observed. PI3K specific inhibitor (LY294002) abolished the augment of PKB, NF-?B P65 and IL-8 expression. Antisense PKB cDNA transfection also abolished the augment of PKB, AP-1, NF-?B P65 and IL-8 expression. Though PAR2 antibody did not inhibit PKB expression, it did inhibit the phosphorylation by tryptase in ECV304 cells. CONCLUSION: These results indicate that tryptase can activate PKB through PAR2 receptor and subsequently NF-?B, AP1, IL-8 and PKB expression.

Objectives To investigate the practical application of modified peritoneal equilibration test (modified PET) employing 4.25% glucose exchange in peritoneal dialysis patients and to assess the reference values and clinical significance of the test. Methods Modified PETs were performed in 97 patients without peritonitis for at least 4 weeks. Mass transfer area coefficient (MTAC) was calculated according to the Garred model. Creatinine D/P concentration ratio at 4 hr (4 h D/Pcr), sodium D/P concentration ratio at 1 hr (1 h D/PNa+) and net ultrafiltration (nUF) were also assessed. Ultrafiltration 0.05). 4 h D/Pcr and MTACcr of modified PET were significantly correlated with 4h D/Pcr of standard PET (P

OBJECTIVETo investigate the antitumor and anti-metastatic effect of in situ transduction of adenovirus encoding cytosine deaminase (AdCD) followed by the systemic use of 5-fluorocytosine (5-FC) in the orthotopic (o.t.) prostate cancer mouse model.

METHODSThe o.t. prostate cancer model of C57BL/6 mouse was developed by o.t. inoculation of RM-1 cells to the subcapsular area of the prostate gland. In situ transduction of the CD gene, followed by systemic use of 5-FC at a daily dosage of 300 mg/kg for 14 days, was performed two days later.

RESULTSCompared with mice treated with Adbeta-gal/5-FC, 5-FC and PBS, mice of the o.t. model receiving in situ treatment of AdCD/5-FC had significant prolongation of survival and suppression of local tumor growth. More importantly, pathological observations showed that metastatic activity occurred in all mice of the PBS, 5-FC and Adbeta-gal groups including metastasis to the iliac lymph node (10/10, 10/10, 10/10) and the lung (8/10, 7/10, 7/10). However, only two out of ten had iliac lymphatic metastasis in the AdCD/5-FC group with no systemic or preaotic lymphatic metastasis, suggesting a strong metastatic inhibitory effect.

CONCLUSIONSIn situ transduction of AdCD followed by systemic use of 5-FC leads to the inhibitory effect on tumor growth and metastatic activity in the o.t. mouse model of prostate cancer. Clinically, it may be possible to treat metastatic or recurrent prostate cancer with a novel gene therapy using in situ injection techniques in future.

Adenoviridae ; genetics ; Animals ; Cell Division ; drug effects ; genetics ; Cytosine Deaminase ; Disease Models, Animal ; Flucytosine ; pharmacology ; Lymphatic Metastasis ; genetics ; pathology ; prevention & control ; Male ; Mice ; Mice, Inbred C57BL ; Neoplasm Transplantation ; Nucleoside Deaminases ; genetics ; Prostatic Neoplasms ; genetics ; mortality ; prevention & control ; Survival Rate ; Transfection ; Tumor Cells, Cultured

Objective To investigate the relationship between MRI and pathological features of uterine carcinosarcoma(UCS).Methods 13 cases of UCS which were confirmed by surgery and pathology were collected,MRI plain scan and enhanced scan were carried on all of the patients,the pathological tissue was got after operation for conventional HE and immunohistochemical staining.The MRI representation and pathological tissue composition of all the 13 cases were analyzed and summarized.Results 8 cases were occurred in uterine body,3 cases were in the cervix and 2 were involving the uterine body and cervix at the same time.The MRI manifestations of them were enlarged uterine size with irregular masses showed,intermediate or hypointensity intensity signal on T1 weighted and hyperintensity or intermediate intensity signal on T2 weighted,necrosis and cystic lesions were showed in 5 cases,2 cases hemorrhage were displaied which showed hyperintensity signal on T1 weighted,4 cases were endometrial thickening,all of the cases were heterogeneous enhancement;the pathological showed different proportion of carcinorma and sarcoma were visible in all the 13 cases of UCS.Conclusion UCS has complex components histopathologically,including both carcinoma tissue and sarcoma tissue.The heterogeneous signal of cystic degeneration,necrosis and hemorrhage within tumor in MRI could help the diagnosis of UCS.

Objective To explore the influence factors of self-care activities and self-efficacy of patients at high risk of diabetic foot .Methods A total of 92 follow-up patients at high risk of diabetic foot in our hospital between June 2013 and January 2015 were selected by convenient sampling and investigated by questionnaires , including demographic data , summary of diabetes self care activities ( SDSCA ) and self-efficacy scale . Results The total score of SDSCA was (30.99 ±12.336), and the score rate was 40.25%.The total score of self-efficacy was (93.34 ±20.603), and the score rate was 71.80%.The family monthly income, marital status, age and gender were influence factors of self-care activities (P<0.05).The smoking, family monthly income, marital status, and occupation were influence factors of self-efficacy (P<0.05).Conclusions The self-care activities and self-efficacy of patients at high risk of diabetic foot is not optimistic .The nurses should pay more attention to the health education of them , in order to reduce the complications and disability rate and improve the quality of life .

Objective:To investigate the efficacy and safety of ixazomib combined with lenalidomide and dexamethasone (IRd) regimen in treatment of multiple myeloma (MM) patients in the real world practice.Methods:The clinical data of 24 MM patients treated with IRd regimen from January 2019 to January 2021 in the Union Hospital, Tongji Medical College, Huazhong University of Science and Technology were retrospectively analyzed, and their efficacy and adverse reactions were analyzed. Among the 24 patients, 5 patients were relapsed and refractory (relapsed/refractory group), and 19 newly treated patients (conversion group) who responded to bortezomib induction therapy but converted to IRd regimen due to adverse reactions or other reasons.Results:The 24 patients were treated for a median of 4 cycles (2-7 cycles), with 8 cases of complete remission (CR), 6 cases of very good partial remission (VGPR), 8 cases of partial remission (PR), 1 case of disease progression (PD), 1 case of minimal response (MR), and the overall response rate (ORR) was 91.7% (22/24); the median progression-free survival (PFS) time was 15 months (95% CI 6.6-23.4 months); 6 CR patients were negative for minimal residual disease (MRD). The common adverse reactions were hematological adverse reactions, peripheral neuropathy, fatigue, gastrointestinal reactions, and infections. The incidence rate of grade 3-4 adverse reactions was 25.0% (6/24). In the relapsed/refractory group, the best efficacy was VGPR in 1 case, PR in 3 cases, and MR in 1 case, all patients withdrew from the IRd regimen therapy due to PD after transient remission or poor effect; in the conversion group, the best efficacy was CR in 8 cases, VGPR in 5 cases, PR in 5 cases, and PD in 1 case, 57.9% (11/19) patients maintained their original best response, and 36.8% (7/19) patients improved their best response to CR; the difference in median PFS time between the two groups was statistically significant (7 months vs. not reached, P = 0.018). Conclusions:The IRd regimen is safe and effective for MM patients, especially for the conversion patients after effective bortezomib induction therapy. Although patients with relapsed/refractory MM who have previously used multi-line therapy respond to IRd regimen, the duration of remission is limited.

Splenic marginal zone lymphoma (SMZL) is a rare indolent B-cell lymphoma. Due to its rarity and the lack of large-scale prospective randomized trials of SMZL, the treatment of SMZL is mainly based on therapy regimens of other indolent lymphomas and expert consensus. Asymptomatic patients can wait and watch, while the traditional treatments of symptomatic patients include splenectomy and chemotherapy alone. Rituxmab monotherapy has become the new first-line option and been widely used because of its good efficacy over the last decades. With the further understanding of molecular etiology of various lymphomas, some novel target agents are under clinical trials in low-grade lymphoma including small amount of SMZL patients. This review mainly discusses the treatment progress of SMZL.

Objective To study the level of hope and influencing factors of hospitalized patients with type 2 diabetes.Methods A total of 340 hospitalized patients with type 2 diabetes in the 6th People′s Hospital affiliated to Shanghai Jiaotong University from October 2014 to June 2015 were selected randomly as the research object. General information questionnaire, Herth hope scale and social support rate scale ( SSRS) were used to investigate the patients.Results The level of hope of patients with type 2 diabetes was medium to high. Score of SSRS was (42.65±6.58), which is higher than national norm (t=21.93,P<0.01); The influencing factors of level of hope in type 2 diabetes patients included the age, economical condition, disease course and social support (β=-2.33,-3.41,3.87,3.94;P<0.05).Conclusions The age, economical condition, disease course and the level of social support are the leading influencing factors for the level of hope in patients with type 2 diabetes. The level of hope of patients with type 2 diabetes could be improved by nursing intervention based on patients′age, economical condition, disease course, and the social support.